EXHIBIT 99.1



|                                                             | NEWS RELEASE                                                                     
|------------------------------------------------------------ | ---------------------------------------------------------------------------------
|For Release: Tuesday, October 25, 2005, 3:05 pm Central Time | Contact: Howard Root, CEO
James Hennen, CFOVascular Solutions, Inc.(763) 656-4300

# VASCULAR SOLUTIONS
ANNOUNCES RECORD THIRD QUARTER RESULTS

Net sales increase
44% from Q3 of 2004 to record $8.6 million.Vascular Solutions achieves second
consecutive profitable quarter.

MINNEAPOLIS,
Minnesota  Vascular Solutions, Inc. (Nasdaq:VASC) today announced its seventh
consecutive quarterly net sales record and its second consecutive quarter of profitability
in its results for the third quarter ended September 30, 2005.

Net
sales during the third quarter were $8,574,000, an increase of 44% from net sales of
$5,974,000 in the third quarter of 2004. The primary contributors to the increase in sales
were continued growth in sales of the D-Stat Dry hemostatic bandage, increasing sales of
the Pronto extraction catheter and increasing sales of the Vari-Lase endovenous laser
product line. In total, over 80% of net sales in the third quarter came from sales of five
new products that Vascular Solutions has launched in the U.S. in the last two years.

The
resulting net income for the third quarter was $60,000 or $0.00 per share, improving from
a net loss of $437,000 or $0.03 per share in the third quarter of 2004. During the third
quarter the company incurred $432,000 in expenses related to the development and
qualification of a new supply of thrombin, a primary component of its hemostatic products.
The substantial majority of the thrombin qualification work and expenses are expected to
be completed by the end of the first half of 2006. As adjusted (excluding the thrombin
expenses and assuming a tax rate of 40%), net income was $295,000 or $0.02 per fully
diluted share.

The
third quarter represented another sequential step in the growth of our business by
advancing new clinically-based interventional medical devices developed, manufactured and
sold by Vascular Solutions, commented Howard Root, Chief Executive Officer of
Vascular Solutions. More than compensating for the normal summer slow-down in
several markets and the disruption of the hurricanes in the gulf coast states, our direct
sales force increased sales sequentially by over $400,000, or 6%, to achieve another new
sales record. Looking forward, we expect to continue to set new quarterly sales records
and increase our profitability on an adjusted basis each quarter for the foreseeable
future.

Net
sales of the D-Stat Dry product line were $3,661,000 during the third quarter, an increase
of 8% sequentially from the second quarter. A total of 521 accounts in the U.S. purchased
the D-Stat Dry in the third quarter, with a stable re-order rate of 79%. In the
third quarter we continued to establish the clinical superiority of the D-Stat Dry and
began our launch of the ThrombiGel product line extension, commented Mr. Root.
We believe that sales of the D-Stat Dry family will continue to increase
sequentially as we maintain and grow our market share.

---

Net
sales of the Pronto extraction catheter totaled $1,686,000 in the third quarter, an
increase of 94% over the third quarter of 2004 and 3% sequentially from the second
quarter. Overcoming the normal summer slowdown in procedures in Europe, we benefited
from a strong continuing launch of the Pronto in Japan, commented Mr. Root. We
remain on track to launch the next version Pronto V3 in the U.S. and European markets in
November, which we expect will substantially increase our Pronto sales into 2006. We also
are very encouraged by the presentation of the final DEAR-MI clinical data at the recent
TCT meeting. All of these developments result in the expectation that the Pronto will be
our fastest growing product line in 2006.

Net
sales of the Vari-Lase endovenous laser product line totaled $1,237,000 in the third
quarter, an increase of 62% over the third quarter of 2004 and 4% sequentially from the
second quarter. We continue to benefit from our sales forces increasing
experience selling capital equipment and providing clinical support on the endovenous
laser procedure, commented Mr. Root. Overcoming the decrease in varicose vein
procedures that happens in the summer months, our direct sales force has used its size and
clinical skills to result in growth that we expect will continue throughout 2006.

Net
sales of the Duett sealing device product line totaled $909,000 in the third quarter of
2005. We continue to support and harvest our Duett product line, and our
direct sales force has maintained the majority of our long-time Duett customers while this
business has continued to decline as forecasted, commented Mr. Root.

Net
sales of the D-Stat Flowable hemostat increased to $590,000 in the third quarter of 2005,
an increase of 15% from $513,000 in the second quarter. The results of our Pocket
Protector clinical study presented at the TCT meeting were favorably received,
commented Mr. Root. We expect to complete the required statistical analysis on this
study and file our PMA Supplement for this new indication of the Flowable by the end of
the year.

Overall
gross margin across all products was 73% in the third quarter, benefiting from the higher
gross margins and increasing sales of the D-Stat Dry and Pronto product lines.

The
company also provided an update on its progress in the development and launch of new
interventional medical devices. During the remainder of 2005, we expect to launch
the Skyway and TwinPass catheters, two specialty purpose catheters for Interventional
cardiology, in addition to the new V3 version of the Pronto, commented Mr. Root.
For 2006, we have the GuideLiner, Gopher, Power Syringe and
Micro-Introducer Catheter products all scheduled for launch throughout the year.

During
the third quarter, the company continued the development and qualification of a new source
of thrombin for use in its hemostatic products. We have finalized our regulatory
strategy and completed our initial pilot runs of the thrombin manufacturing process which
puts us on track for the approval of the use of the new thrombin in our hemostatic
products in early 2007 and the approval to sell Thrombin-VSI into the $250 million annual
U.S. thrombin market in 2008, Mr. Root commented.

---

The
company also issued guidance for the fourth quarter of 2005 and the year 2006. Net sales
for the fourth quarter are expected to increase to between $9.2 million and $9.5 million.
Net sales for 2006 are expected to increase to between $44 million and $46 million. Longer
term, net sales are expected to continue to increase by at least 30% annually over the
next several years. Adjusted net earnings per share (excluding thrombin qualification
expenses and stock based compensation expenses, but fully taxed and computed on a fully
diluted basis) are expected to be between $0.15 and $0.20 in 2006. We believe that
this strategy of adding a variety of new clinically-based products sold by a focused
direct sales force will allow us to achieve our next long term milestone of $100 million
in annual sales by 2009, concluded Mr. Root.

# Conference Call &
Webcast Information

Vascular
Solutions will host a live webcast starting at 3:30 p.m., Central Time today to discuss
the information contained in this press release. The live web cast may be accessed on the
investor relations portion of our web site at www.vascularsolutions.com. Web
participants are encouraged to go to the web site at least 15 minutes prior to the start
of the call to download and install any necessary audio software. An audio replay of the
call will be available until Tuesday, November 8 by dialing 1-800-642-1687 and entering
conference ID #1185803. A recording of the call will also be archived on the investor
relations portion of the Companys web site, www.vascularsolutions.com
until Tuesday, November 8. During the conference call the Company may answer one or more
questions concerning business and financial developments and trends, the Companys
view on earnings forecasts and new product development and financial matters affecting the
Company, some of the responses to which may contain information that has not been
previously disclosed.

---

VASCULAR SOLUTIONS, INC.CONDENSED STATEMENTS OF
OPERATIONS

|(In thousands, except per share data)                 |  | Three Months Ended |   | Nine Months Ended
|----------------------------------------------------- |  | ------------------ | - | -----------------
|
|
|
|
|                                                     
|Net sales                                             |  |                    | $ | 8,574            
|Cost of goods sold                                    |  |                    |   | 2,330            
|                                                      |  |                    |   |                  
|Gross profit                                          |  |                    |   | 6,244            
|                                                     
|Operating expenses:                                   |  |                   
|Research and development                              |  |                    |   | 865              
|Clinical and regulatory                               |  |                    |   | 556              
|Sales and marketing                                   |  |                    |   | 3,566            
|General and administrative                            |  |                    |   | 755              
|Thrombin qualification                                |  |                    |   | 432              
|Amortization of purchased technology                  |  |                    |   | 54               
|                                                     
|Operating income (loss)                               |  |                    |   | 16               
|Interest income                                       |  |                    |   | 44               
|Net income (loss)                                     |  |                    | $ | 60               
|                                                      |  |                    |   |                  
|                                                     
|Net income (loss) per share - basic                   |  |                    | $ | 0.00             
|                                                      |  |                    |   |                  
|Weighted average shares used in calculating - basic   |  |                    |   | 14,579           
|                                                      |  |                    |   |                  
|Net income (loss) per share - diluted                 |  |                    | $ | 0.00             
|                                                      |  |                    |   |                  
|Weighted average shares used in calculating - diluted |  |                    |   | 15,670           
|                                                      |  |                    |   |                  

---

VASCULAR SOLUTIONS, INC.CONDENSED BALANCE SHEETS

|                                                           |  | September 30, 2005 |   | December 31, 2004
|---------------------------------------------------------- |  | ------------------ | - | -----------------
|
|
|ASSETS                                                     |  |                    |   |                  
|Current assets:                                            |  |                   
|Cash and cash equivalents                                  |  |                    | $ | 6,175            
|Accounts receivable, net                                   |  |                    |   | 4,643            
|Inventories                                                |  |                    |   | 4,638            
|Prepaid expenses                                           |  |                    |   | 726              
|                                                           |  |                    |   |                  
|Total current assets                                       |  |                    |   | 16,182           
|Property and equipment, net                                |  |                    |   | 2,238            
|Intangible assets                                          |  |                    |   | 319              
|                                                           |  |                    |   |                  
|Total assets                                               |  |                    | $ | 18,739           
|                                                           |  |                    |   |                  
|                                                          
|LIABILITIES AND SHAREHOLDERS EQUITY                       |  |                   
|Current liabilities:                                       |  |                   
|Total current liabilities                                  |  |                    | $ | 4,489            
|Shareholders equity:                                      |  |                   
|Total shareholders equity                                 |  |                    |   | 14,250           
|                                                           |  |                    |   |                  
|Total liabilities and shareholders equity                 |  |                    | $ | 18,739           
|                                                           |  |                    |   |                  
|Note: Derived from the audited
balance sheet at that date.

# Use of Non-GAAP Measures

Management
uses non-GAAP measures to establish operational goals, and believes that non-GAAP measures
may assist investors in analyzing the underlying trends in the Companys business
over time. Investors should consider these non-GAAP measures in addition to, not as a
substitute for or as superior to, financial reporting measures prepared in accordance with
GAAP. In this press release, the Company has reported a non-GAAP measure called adjusted
net income which excludes certain expenses relating to the qualification of a new supply
of thrombin. On October 18, 2004, the Company entered into a supply agreement with
Sigma-Aldrich Fine Chemicals for the development, manufacture and supply of bulk thrombin
for use in the Companys hemostatic products. The Company estimates that the
development and qualification of this new supply of thrombin will take approximately two
years to complete, with estimated expenditures through the end of 2006 expected to be
approximately $4.1 million in operating expenses, $2.5 million in inventory purchases (in
addition to inventory purchased from the current supplier of thrombin) and $0.8 million in
capital equipment purchases. The Company has incurred approximately $1.3 million of the
expenses, none of the inventory and $0.6 million of the capital expenditures to date.
Management believes that although the qualification expenses are a recurring cost it is
useful to exclude them from net income given the short duration of these expenses and the
expectation that similar expenses will not need to be incurred for the foreseeable future.
Management uses the adjusted net income measure in its internal analysis and review of
operational performance. Management includes the thrombin qualification expenses as well
as the related inventory and capital equipment purchases in its cash projections.
Management believes that this adjusted net income measure provides investors with useful
information in comparing the Companys performance over different periods,
particularly when comparing this period to periods in which the Company did not incur any
expenses relating to the qualification of its new thrombin supply. By using this non-GAAP
measure management believes that investors get a better picture of the performance of the
Companys underlying business. Management encourages investors to review the
Companys net income prepared in accordance with GAAP to understand the
Companys performance taking into account all relevant factors, including those that
may only occur from time to time but have a material impact on the Companys
financial results.

---

# About Vascular Solutions

Vascular
Solutions, Inc. is a medical device company that focuses on developing unique solutions
for unmet clinical opportunities within Interventional radiology and Interventional
cardiology. New products introduced since the second half of 2003 include the
Vari-Lase® endovenous laser product line for the treatment of varicose veins, the
D-Stat Dry hemostatic bandage for the rapid control of topical bleeding, the
Pronto extraction catheter for the mechanical extraction of soft thrombus and the
Langston dual lumen catheter for the measurement of aortic stenosis. The
Companys other major products include the Duett sealing device to rapidly seal
the puncture site following catheterization procedures and the D-Stat® Flowable
hemostat for the local management of active bleeding.

The
information in this press release contains forward-looking statements that involve risks
and uncertainties. Our actual results could differ materially from those anticipated in
these forward-looking statements. Important factors that may cause such differences
include those discussed in our Annual Report on Form 10-K for the year ended December 31,
2004 and other recent filings with the Securities and Exchange Commission. The risks and
uncertainties include, without limitation, risks associated with the need for adoption of
our new products, limited working capital, lack of profitability, exposure to intellectual
property claims, dependence on key vendors, exposure to possible product liability claims,
the development of new products by others, doing business in international markets,
limited manufacturing experience, the availability of third party reimbursement, and
actions by the FDA.

For
further information, connect to www.vascularsolutions.com.

# # #

---